期刊文献+

急性早幼粒细胞白血病预后生存模型的建立 被引量:3

Establishment of survival model for predicting prognosis of patients with acute promyelocytic leukemia
下载PDF
导出
摘要 目的分析影响急性早幼粒细胞白血病(APL)预后的危险因素,并以多参数指标建立APL患者的预后生存模型。方法选取2013年7月—2017年7月浙江大学医学院附属第一医院218例APL患者作为研究对象,将患者分为早期死亡组(18例)和非早期死亡组(200例),分析影响APL预后的危险因素,并建立预后生存模型。结果年龄>60岁、白细胞(WBC)计数>10×10~9/L、纤维蛋白原(Fib)≤1.4 g/L、血清肌酐(SCr)>105μmol/L、血清乳酸脱氢酶(LDH)>250 U/L、早幼粒细胞白血病-维甲酸受体α(PML-RARa)融合基因SG阳性与APL患者早期死亡密切相关(P<0.05);多因素Logistic回归分析发现,年龄[比值比(OR)=1.049,95%可信区间(CI)为1.003~1.098,P=0.038]和WBC计数(OR=1.030,95%CI为1.007~1.054,P=0.012)为APL患者预后的独立危险因素;预后生存模型根据初诊时APL患者年龄、WBC计数、Fib、LDH、SCr、PML-RARa融合基因亚型6项指标建立,其受试者工作特征(ROC)曲线的曲线下面积(AUC)为0.797,敏感性为71.4%,特异性为92.6%。结论年龄、WBC计数为APL预后的独立危险因素,所建立的预后生存模型对预测患者生存状态有重要意义。 Objective To analyze the risk factors for the prognosis of acute promyelocytic leukemia(APL),and to establish the survival model of APL with multiple parameters.Methods A total of 218 patients with APL treated in our hospital from July 2013 to July 2017 were enrolled.The patients were divided into early death group(18 cases)and non-early death group(200 cases).The risk factors for the prognosis of APL were analyzed,and the survival model was established.Results Patient’s age>60 years old,white blood cell(WBC)count>10×10~9/L,fibrinogen(Fib)≤1.4 g/L,serum creatinine(SCr)>105μmol/L,lactate dehydrogenase(LDH)>250 U/L,positive PML-RARαfusion gene SG were closely related to early death(P<0.05).Multivariate Logistic analysis showed that age[odds ratio(OR)=1.049,95%confidence interval(CI)1.003-1.098,P=0.038]and WBC count(OR=1.030,95%CI 1.007-1.054,P=0.012)were independent risk factors for APL prognosis.The model for predicting the patient’s survival was established by the indicators of age,WBC count,Fib,LDH,SCr,and PMLRARαfusion gene subtype at initial diagnosis,and evaluated by receiver operating characteristic(ROC)curve.The area under curve(AUC)was 0.797,the sensitivity was 71.4%,and the specificity was 92.6%.Conclusions Age and WBC count are independent risk factors for APL prognosis.The established model can be explored in predicting the survival status of patients.
作者 沈晓雅 娄引军 王文娟 SHEN Xiaoya;LOU Yinjun;WANG Wenjuan(Department of Clinical Laboratory,the First Affiliated Hospital of Medical College of Zhejiang University,Hangzhou 310000,Zhejiang,China;Department of Hematology,the First Affiliated Hospital of Medical College of Zhejiang University,Hangzhou 310000,Zhejiang,China)
出处 《检验医学》 CAS 2021年第3期292-295,共4页 Laboratory Medicine
关键词 急性早幼粒细胞白血病 早期死亡 预后生存模型 Acute promyelocytic leukemia Early death Survival model
  • 相关文献

参考文献3

二级参考文献24

  • 1孙爱宁,周海侠,吴德沛,王玮,金正明,仇惠英.急性早幼粒细胞白血病PML/RARα异型的临床意义[J].中国实验血液学杂志,2005,13(3):500-502. 被引量:8
  • 2张莉,李睿,李大鹏,刘永泽,徐世才,郝玉书,肖志坚.急性早幼粒细胞白血病治疗的远期疗效观察[J].中华血液学杂志,2007,28(1):15-18. 被引量:11
  • 3WangZY, ChenZ. Acute promyelocytic leukemia: from highly fatal to highly curable [J]. Blood, 2008,111(5):2505-2515. doi: 10.1182/blood-2007-07-102798.
  • 4AdèsL, GuerciA, RaffouxE, et al. Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience[J]. Blood, 2010, 115(9):1690-1696. doi: 10.1182/blood-2009-07-233387.
  • 5BurnettAK, HillsRK, GrimwadeD, et al. Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trial [J]. Leukemia, 2013, 27(4):843-851. doi: 10.1038/leu.2012.360.
  • 6AvvisatiG, Lo-CocoF, PaoloniFP, et al. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance[J]. Blood, 2011, 117(18):4716-4725. doi: 10.1182/blood-2010-08-302950.
  • 7SanzMA, GrimwadeD, TallmanMS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European Leukemia Net[J]. Blood, 2009, 113(9):1875-1891. doi: 10.1182/blood-2008-04-150250.
  • 8SanzMA, MartínG, GonzálezM, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group [J]. Blood, 2004, 103(4):1237-1243. doi: 10.1182/blood-2003-07-2462.
  • 9SanzMA, LoCF, MartínG, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups[J]. Blood, 2000, 96(4):1247-1253.
  • 10FrankelSR, EardleyA, LauwersG, et al. The "retinoic acid syndrome" in acute promyelocytic leukemia [J]. Ann Intern Med, 1992, 117(4):292-296.

共引文献72

同被引文献27

引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部